Xenetic Biosciences, Inc. (XBIOW) Stock Analysis
DELISTED 2024
What happened to Xenetic Biosciences, Inc. (XBIOW) stock?
Xenetic Biosciences, Inc. (XBIOW) no longer trades on public markets. It was delisted in July 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Xenetic Biosciences, Inc. (XBIOW) trades at $17.54. Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology targeting patient-specific tumor neoantigens. Market cap: $5.62M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for XBIOW: XBIOW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XBIOW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
XBIOW: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Xenetic Biosciences, Inc. (XBIOW) Healthcare & Pipeline Overview
Xenetic Biosciences, Inc. is a biopharmaceutical firm specializing in personalized CAR T-cell therapies and biologic drug development. Their XCART platform targets patient-specific tumor neoantigens, while the PolyXen drug delivery system is leveraged through strategic partnerships within the biotechnology and pharmaceutical sectors, operating in a competitive and rapidly evolving healthcare landscape.
What Is the Investment Thesis for XBIOW?
Xenetic Biosciences presents a high-risk, high-reward investment profile centered on its XCART platform and PolyXen technology. The potential success of XCART in treating B-cell lymphomas through personalized CAR T-cell therapy could drive significant value. The company's partnerships, including those with Takeda, Serum Institute of India, and PJSC Pharmsynthez, provide validation and potential revenue streams. However, the company's small market capitalization of $5.62M and negative P/E ratio of -2.58 reflect its early stage and inherent risks. Investors should carefully consider the clinical trial outcomes, regulatory hurdles, and competitive landscape before investing. The high beta of 2.30 indicates significant volatility, making it suitable only for risk-tolerant investors.
Based on FMP financials and quantitative analysis
XBIOW Key Highlights
Market capitalization of $5.62M, indicating a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -2.58, reflecting the company's current lack of profitability due to ongoing research and development expenses.
- Gross margin of 74.3%, suggesting strong potential for profitability once products reach commercialization.
- Beta of 2.30, indicating high volatility compared to the overall market, making it a speculative investment.
- Focus on personalized CAR T-cell therapy with the XCART platform, representing a cutting-edge approach to cancer treatment.
Who Are XBIOW's Competitors?
XBIOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ENTO ENTO | $2.85 | -5.00% | $13.6M | 49 |
| FRTX Fresh Tracks Therapeutics, Inc. | $0.94 | -0.53% | $5.59M | 54 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XBIOW's Key Strengths?
Proprietary XCART platform for personalized CAR T-cell therapy.
- PolyXen drug delivery platform with potential for broad applications.
- Strategic partnerships with established pharmaceutical companies.
- Focus on innovative approaches to drug development and personalized medicine.
What Are XBIOW's Weaknesses?
Limited financial resources and small market capitalization.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- High research and development costs.
- Limited number of employees.
What Could Drive XBIOW Stock Higher?
Clinical trial results for XCART in B-cell lymphomas.
- Potential new partnerships leveraging the PolyXen drug delivery platform.
- Regulatory submissions and approvals for XCART and other pipeline candidates.
What Are the Key Risks for XBIOW?
Financial-distress signal — its Altman Z-Score of -36.44 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-40.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or setbacks.
- Regulatory hurdles and delays.
- Competition from other biotechnology and pharmaceutical companies.
- Dependence on successful partnerships and collaborations.
- Limited financial resources and need for additional funding.
What Are the Growth Opportunities for XBIOW?
- Expansion of XCART Platform: Xenetic Biosciences has the opportunity to expand the application of its XCART platform beyond B-cell lymphomas to other hematological malignancies and solid tumors. Successful clinical trials and regulatory approvals could significantly increase the company's market share.
- Strategic Partnerships: Xenetic Biosciences can leverage its PolyXen drug delivery platform to forge additional strategic partnerships with biotechnology and pharmaceutical companies. These partnerships can provide access to new markets, funding, and expertise, accelerating the development and commercialization of products utilizing the PolyXen technology. The pharmaceutical industry is increasingly seeking innovative drug delivery solutions to improve the efficacy and safety of existing and novel therapies.
- Clinical Trial Advancement: Advancing its clinical trial programs for XCART and other pipeline candidates represents a significant growth opportunity for Xenetic Biosciences. Positive clinical trial results can validate the efficacy and safety of its therapies, attracting investor interest and paving the way for regulatory approvals. The company's ability to efficiently manage clinical trials and secure regulatory approvals will be crucial to its long-term success.
- Intellectual Property Protection: Strengthening its intellectual property portfolio through patents and other forms of protection is essential for Xenetic Biosciences to maintain its competitive advantage. A strong IP position can deter competitors and provide exclusive rights to its technologies and therapies. The company should continue to invest in research and development to generate new intellectual property and expand its patent portfolio.
- Market Expansion: Xenetic Biosciences can explore opportunities to expand its market presence beyond its current geographic focus. This could involve establishing collaborations with international partners, conducting clinical trials in new regions, and seeking regulatory approvals in additional countries. The global market for biotechnology products is growing rapidly, driven by increasing healthcare spending and the rising prevalence of chronic diseases.
What Threats Does XBIOW Face?
- Intense competition from other biotechnology and pharmaceutical companies.
- Uncertainty in clinical trial outcomes and regulatory approvals.
- Potential for product failures and setbacks.
- Changes in healthcare regulations and reimbursement policies.
What Are XBIOW's Competitive Advantages?
- Proprietary XCART platform for personalized CAR T-cell therapy.
- PolyXen drug delivery platform with potential for broad applications.
- Strategic partnerships with established pharmaceutical companies.
What Does XBIOW Do?
Xenetic Biosciences, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel biologic drugs and cell-based therapeutics. The company's primary focus is on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology. XCART is engineered to target patient-specific tumor neoantigens, offering a potential breakthrough in cancer treatment by creating therapies tailored to the unique characteristics of each patient's tumor. Xenetic Biosciences also leverages its proprietary PolyXen drug delivery platform, which enhances the properties of biologic drugs, improving their efficacy, safety, and ease of administration. This platform is utilized both internally and through strategic partnerships with biotechnology and pharmaceutical companies. Xenetic Biosciences has established collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez to further develop and commercialize products utilizing the PolyXen technology. Headquartered in Framingham, Massachusetts, Xenetic Biosciences is committed to addressing unmet medical needs through innovative approaches to drug development and personalized medicine.
What Products and Services Does XBIOW Offer?
- Develops personalized CAR T-cell therapies targeting patient-specific tumor neoantigens.
- Focuses on advancing the XCART platform for the treatment of B-cell lymphomas.
- Leverages the PolyXen drug delivery platform to enhance the properties of biologic drugs.
- Engages in strategic partnerships with biotechnology and pharmaceutical companies.
- Conducts research and development activities to discover and develop novel biologic drugs and therapeutics.
- Aims to address unmet medical needs through innovative approaches to drug development and personalized medicine.
How Does XBIOW Make Money?
- Develops and out-licenses its PolyXen technology to other pharmaceutical companies.
- Focuses on research and development of its XCART platform for personalized cancer therapies.
- Generates revenue through collaboration agreements and potential future product sales.
What Industry Does XBIOW Operate In?
Xenetic Biosciences operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for CAR T-cell therapies is rapidly expanding, driven by advancements in immunotherapy and personalized medicine. Xenetic's XCART platform aims to address the limitations of existing CAR T-cell therapies by targeting patient-specific tumor neoantigens. The company also competes with other biotechnology firms in the development and commercialization of biologic drugs utilizing drug delivery platforms. Key trends in the industry include the increasing adoption of personalized medicine, the growing demand for innovative cancer therapies, and the rising importance of strategic partnerships.
Who Are XBIOW's Key Customers?
- Biotechnology companies seeking drug delivery solutions.
- Pharmaceutical companies looking to enhance their biologic drugs.
- Patients with B-cell lymphomas who may benefit from XCART therapy.
How Xenetic Biosciences, Inc. Is Valued
Xenetic Biosciences, Inc. carries a market capitalization of $5.62M, placing it in the micro-cap category.
Company Profile
Xenetic Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Framingham, US. The company is led by CEO James F. Parslow. XBIOW has traded publicly since 2019.
Key Financial Metrics
Return on equity for Xenetic Biosciences, Inc. stands at -40.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -41.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.43 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Xenetic Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -36.44 places it in the distress zone, a signal of elevated financial risk.
XBIOW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary XCART platform for personalized CAR T-cell therapy.
- PolyXen drug delivery platform with potential for broad applications.
- Strategic partnerships with established pharmaceutical companies.
- Focus on innovative approaches to drug development and personalized medicine.
Bear Case
- Limited financial resources and small market capitalization.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- High research and development costs.
- Limited number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
XBIOW Latest News
No recent news available for XBIOW.
Leadership: James F. Parslow
CEO
James F. Parslow serves as the CEO of Xenetic Biosciences, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and financial management. He has held leadership positions at various biotechnology companies, contributing to the development and commercialization of novel therapies. Parslow's expertise encompasses areas such as drug development, regulatory affairs, and commercial operations. He is responsible for overseeing the company's strategic direction, managing its operations, and driving its growth initiatives.
Track Record: Under James F. Parslow's leadership, Xenetic Biosciences has focused on advancing its XCART platform and PolyXen technology. He has overseen the company's strategic partnerships and clinical trial programs. Key milestones include securing collaboration agreements with Takeda, Serum Institute of India, and PJSC Pharmsynthez. Parslow's tenure has been marked by efforts to strengthen the company's financial position and advance its pipeline of novel therapies.
Xenetic Biosciences, Inc. Healthcare Stock: Key Questions Answered
What happened to Xenetic Biosciences, Inc. (XBIOW) stock?
Xenetic Biosciences, Inc. (XBIOW) no longer trades on public markets. It was delisted in July 2024. The figures below are historical and are not a current quote.
Can I still buy XBIOW shares?
No. XBIOW stopped trading on public markets in July 2024, so the shares are not available through a broker. Anything you see quoted for XBIOW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before XBIOW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Xenetic Biosciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing personalized cell-based therapeutics and novel biologic drugs. The company's primary focus is on its XCART platform, a personalized CAR T-cell therapy designed to target patient-specific tumor neoantigens. They also leverage their PolyXen drug delivery platform to improve the efficacy and safety of biologic drugs, both internally and through partnerships.
What do analysts say about XBIOW stock?
As of March 17, 2026, there is no available AI analysis for XBIOW. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions. Key valuation metrics to consider include market capitalization, P/E ratio, and gross margin.
What are the main risks for XBIOW?
Xenetic Biosciences faces several risks inherent in the biotechnology industry. These include the uncertainty of clinical trial outcomes, the potential for regulatory delays or rejections, intense competition from larger and more established companies, and the need for significant capital to fund research and development activities. The company's small market capitalization and limited financial resources also pose risks. Investors should carefully consider these factors before investing in XBIOW.
How does Xenetic Biosciences, Inc. manage patent expiration risks?
As of March 17, 2026, there is no information available regarding Xenetic Biosciences, Inc.'s specific strategies for managing patent expiration risks. However, biotechnology companies typically employ several strategies, including filing new patent applications for improved formulations or methods of use, developing new products to replace those facing patent expiration, and pursuing strategic partnerships to extend the lifecycle of existing products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited source data. AI analysis is pending.